What the company actually pays, and whether its own cash supports it.
What stands out
Pays more per share than it earned over the last twelve months
Dividends view
Yield
8.32%Above 5Y avg (3.43%)
Annual Rate
CNY 1.27Paid annual
Payout Ratio
144.3%High
Payback Period
9.4 yr
Last Ex-Dividend
Jun 12, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.37BCNY
355.09M · vs all stocks (USD)
Updated Oct 23, 2026
Trailing P/E
17.56x
vs Pharmaceutical Retailers peers
Updated Oct 23, 2026
Revenue (TTM)
8.65BCNY
1.30B · vs all stocks (USD)
Updated Oct 23, 2026
Profit Margin
1.50%
vs Pharmaceutical Retailers peers
Updated Oct 23, 2026
Beta
0.5210x
vs all stocks
Updated Oct 23, 2026
52-Week Change
-28.08%
vs all stocks
Updated Oct 23, 2026
Market Capitalization
2.37BCNY
355.09M · vs all stocks (USD)
Updated Oct 23, 2026
Enterprise Value
5.51BCNY
826.95M · vs all stocks (USD)
Updated Oct 23, 2026
Trailing P/E
17.56x
vs Pharmaceutical Retailers peers
Updated Oct 23, 2026
Price to Sales (TTM)
0.2699x
vs Pharmaceutical Retailers peers
Updated Oct 23, 2026
Price to Book (MRQ)
0.8815x
vs Pharmaceutical Retailers peers
Updated Oct 23, 2026
Enterprise to Revenue
0.6380x
vs Pharmaceutical Retailers peers
Updated Oct 23, 2026
Enterprise to EBITDA
13.12x
vs Pharmaceutical Retailers peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 4.52×.Updated Oct 23, 2026
Gross Margin
37.15%
vs Pharmaceutical Retailers peers
Updated Oct 23, 2026
Profit Margin
1.50%
vs Pharmaceutical Retailers peers
Updated Oct 23, 2026
Operating Margin
2.95%
vs Pharmaceutical Retailers peers
Updated Oct 23, 2026
Return on Assets (TTM)
2.31%
vs Pharmaceutical Retailers peers
Updated Oct 23, 2026
Return on Equity (TTM)
5.04%
vs Pharmaceutical Retailers peers
Updated Oct 23, 2026
Revenue (TTM)
8.65BCNY
1.30B · vs all stocks (USD)
Updated Oct 23, 2026
Revenue per Share (TTM)
58.51CNYUpdated Oct 23, 2026
Quarterly Revenue Growth
-3.30%
vs Pharmaceutical Retailers peers
Updated Oct 23, 2026
Gross Profit (TTM)
3.13BCNY
469.55M · vs all stocks (USD)
Updated Oct 23, 2026
EBITDA (TTM)
1.22BCNY
182.83M · vs all stocks (USD)
Updated Oct 23, 2026
Net Income (TTM)
129.42MCNY
19.41M · vs all stocks (USD)
Updated Oct 23, 2026
Quarterly Earnings Growth (YoY)
-54.40%
vs Pharmaceutical Retailers peers
Updated Oct 23, 2026
Operating Cash Flow (TTM)
1.21BCNY
182.06M · vs all stocks (USD)
Updated Oct 23, 2026
Levered Free Cash Flow (TTM)
1.19BCNY
178.79M · vs all stocks (USD)
Updated Oct 23, 2026
Trailing Annual Dividend Rate
1.27CNYUpdated Oct 23, 2026
Trailing Annual Dividend Yield
8.32%
vs all stocks
Updated Oct 23, 2026
5-Year Average Dividend Yield
3.43%
vs all stocks
Updated Oct 23, 2026
Payout Ratio
144.32%
vs Pharmaceutical Retailers peers
Provider-reported. Trailing Annual Dividend Rate ÷ Diluted EPS (TTM) on this page gives 147.67%.Updated Oct 23, 2026
Minority Interest (Equity)
-1.31MCNYFY2025 · Dec 31, 2025
Revenue
8.92BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
5.70BCNYFY2025 · Dec 31, 2025
Gross Profit
3.22BCNYFY2025 · Dec 31, 2025
Operating Income
425.65MCNY
63.84M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
207.16MCNYFY2025 · Dec 31, 2025
Income Tax Expense
59.04MCNYFY2025 · Dec 31, 2025
Net Income
148.12MCNYFY2025 · Dec 31, 2025
EBIT
327.88MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
1.22BCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
658.39MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
38.76MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
3.36MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
120.72MCNYFY2025 · Dec 31, 2025
EPS (Basic)
1.00CNYFY2025 · Dec 31, 2025
EPS (Diluted)
1.00CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
148.15MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
148.15MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
148.12MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
33.44KCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
786.15MCNYFY2025 · Dec 31, 2025
Free Cash Flow
665.74MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
301.87MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
148.12MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
283.00MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-623.75MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
978.78MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-120.40MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-51.39MCNYFY2025 · Dec 31, 2025
Sale of Investments
100.50MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-71.29MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
1.32BCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-1.29BCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-242.90MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-784.14MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
-997.31MCNYFY2025 · Dec 31, 2025
Shares Outstanding
154.54MSharesUpdated Oct 23, 2026
Float Shares
66.84MSharesUpdated Oct 23, 2026
% Held by Insiders
54.43%
vs all stocks
Updated Oct 23, 2026
% Held by Institutions
3.47%
vs all stocks
Updated Oct 23, 2026
Total Cash (MRQ)
870.83MCNY
130.61M · vs all stocks (USD)
Updated Oct 23, 2026
Total Cash per Share (MRQ)
5.88CNYUpdated Oct 23, 2026
Total Debt (MRQ)
4.11BCNY
616.23M · vs all stocks (USD)
Updated Oct 23, 2026
Total Debt to Equity (MRQ)
1.62x
vs Pharmaceutical Retailers peers
Updated Oct 23, 2026
Current Ratio (MRQ)
0.7640x
vs Pharmaceutical Retailers peers
Updated Oct 23, 2026
Book Value per Share (MRQ)
17.13CNYUpdated Oct 23, 2026
Total Assets
9.75BCNY
1.46B · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
4.33BCNYFY2025 · Dec 31, 2025
Total Liabilities
7.08BCNYFY2025 · Dec 31, 2025
Total Non-current Assets
5.42BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
1.70BCNYFY2025 · Dec 31, 2025
Total Current Liabilities
5.38BCNYFY2025 · Dec 31, 2025
Cash
275.03MCNYFY2025 · Dec 31, 2025
Cash Equivalents
603.55MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
878.58MCNYFY2025 · Dec 31, 2025
Accounts Receivable
1.06BCNYFY2025 · Dec 31, 2025
Inventory
2.11BCNYFY2025 · Dec 31, 2025
Accounts Payable
2.25BCNYFY2025 · Dec 31, 2025
Short-term Debt
2.80BCNYFY2025 · Dec 31, 2025
Other Current Liabilities
2.33MCNYFY2025 · Dec 31, 2025
Long-term Debt
1.48BCNYFY2025 · Dec 31, 2025
Common Stock (Book)
154.54MCNYFY2025 · Dec 31, 2025
Retained Earnings
1.17BCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
2.67BCNY
400.70M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
145.44MCNYFY2025 · Dec 31, 2025
52-Week Low
14.41CNYUpdated Oct 23, 2026
52-Week High
22.30CNYUpdated Oct 23, 2026
52-Week Change
-28.08%
vs all stocks
Updated Oct 23, 2026
Beta
0.5210x
vs all stocks
Updated Oct 23, 2026
50-Day MA
16.02CNYUpdated Oct 23, 2026
200-Day MA
17.92CNYUpdated Oct 23, 2026
Avg 10-Day Volume
1.38MSharesUpdated Oct 23, 2026
Avg 30-Day Volume
1.38MSharesUpdated Oct 23, 2026
Diluted EPS (TTM)
0.8600CNYUpdated Oct 23, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 37.2%, higher than 95% of its Pharmaceutical Retailers peers (median 24.2%)Significant